Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - LogicBio Therapeutics, Inc. | logc-ex321_9.htm |
| EX-31.2 - EX-31.2 - LogicBio Therapeutics, Inc. | logc-ex312_1069.htm |
| EX-31.1 - EX-31.1 - LogicBio Therapeutics, Inc. | logc-ex311_1068.htm |
| EX-21.1 - EX-21.1 - LogicBio Therapeutics, Inc. | logc-ex211_7.htm |
| EX-10.22 - EX-10.22 - LogicBio Therapeutics, Inc. | logc-ex1022_360.htm |
| EX-10.20 - EX-10.20 - LogicBio Therapeutics, Inc. | logc-ex1020_407.htm |
| EX-10.6 - EX-10.6 - LogicBio Therapeutics, Inc. | logc-ex106_402.htm |
| EX-10.4 - EX-10.4 - LogicBio Therapeutics, Inc. | logc-ex104_401.htm |
| EX-10.2 - EX-10.2 - LogicBio Therapeutics, Inc. | logc-ex102_404.htm |
| EX-4.4 - EX-4.4 - LogicBio Therapeutics, Inc. | logc-ex44_403.htm |
| 10-K - 10-K - LogicBio Therapeutics, Inc. | logc-10k_20191231.htm |
Exhibit23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement No. 333-234735 on Form S-3 and Registration Statement No. 333-230698 on Form S-8 of our report dated March 16, 2020, relating to the financial statements of LogicBio Therapeutics, Inc. appearing in this Annual Report on Form 10-K of LogicBio Therapeutics, Inc. for the year ended December 31, 2019.
|
/s/ Deloitte & Touche LLP |
|
|
|
Boston, Massachusetts |
|
March 16, 2020 |